- Boehringer Ingelheim obtained worldwide rights to a preclinical antibody program from Immunitas Therapeutics to develop, manufacture and commercialize treatments for chronic inflammatory diseases.
- The antibody is designed to selectively target pathogenic cells localized at inflammation sites to provide deeper, more durable control than therapies that block individual inflammatory signals.
- Immunitas will receive an upfront payment plus development, regulatory and commercial milestones totaling up to €407.5 million, in addition to tiered royalties.
Deal overview
Boehringer Ingelheim has licensed a preclinical antibody program from Immunitas Therapeutics, acquiring worldwide rights to develop, manufacture and commercialize the asset for chronic inflammatory and autoimmune diseases.
Program profile
The antibody is designed to selectively target a subset of pathogenic cells localized at sites of inflammation rather than blocking individual inflammatory signals, with the intent of delivering deeper and more durable disease control for patients who respond inadequately to current therapies.
Financial terms and development plan
Immunitas will receive an upfront payment plus near‑term and future development, regulatory and commercial milestone payments totaling up to €407.5 million, in addition to tiered royalties; Boehringer Ingelheim will advance the program toward clinical development leveraging its global R&D, manufacturing and commercialization capabilities.
